Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/13/2003WO2003061554A3 Composition containing moutan root bark extract as active ingredient
11/13/2003WO2003061553A3 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
11/13/2003WO2003059354A3 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
11/13/2003WO2003057688A3 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
11/13/2003WO2003057672A3 Tetrahydroquinoline analogues as muscarinic agonists
11/13/2003WO2003057165A3 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
11/13/2003WO2003053966A3 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
11/13/2003WO2003053331A3 Protease inhibitors
11/13/2003WO2003045305A3 Acetaminophen compositions
11/13/2003WO2003045225A3 Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of muc5ac
11/13/2003WO2003041648A3 High-concentration lidocaine compositions and methods for their preparation
11/13/2003WO2003041644A3 Method to treat cystic fibrosis
11/13/2003WO2003041563A3 Neurotransmitter balance chemotherapy
11/13/2003WO2003040691A3 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
11/13/2003WO2003035008A3 Functionalized stilbene derivatives as improved vascular targeting agents
11/13/2003WO2003034992A3 Diindolylmethane for the treatment of hpv infection
11/13/2003WO2003032948A3 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
11/13/2003WO2003032897A3 Azabicyclic compounds for the treatment of fibromyalgia syndrome
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029221A8 Tetrahydroisochinolines, their production and the use thereof as analgesics
11/13/2003WO2003029213A9 Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003028727A9 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
11/13/2003WO2003028667A3 Semisolid topical hormonal compositions and methods for treatment
11/13/2003WO2003027316A3 Methods of using 33751, a human potassium channel family member
11/13/2003WO2003024448A3 Inhibitors of histone deacetylase
11/13/2003WO2003022806A3 Cbi analogues of cc-1065 and the duocarmycins
11/13/2003WO2003020262A3 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003017939A3 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
11/13/2003WO2003017921A3 A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes
11/13/2003WO2003015780A3 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
11/13/2003WO2003015703A3 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
11/13/2003WO2003015605A3 Use of s-nitrosothiol signaling to treat disordered control of breathing
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003009820B1 Methods for promotion of hair growth comprising topical application of prostaglandin analogues
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003002755A3 Glaucoma treatments with reduced hyperpigmentation
11/13/2003WO2003000889A3 Identification of ses-1 and the uses of the same
11/13/2003WO2002098849A3 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002092831A3 Method for identifying ligands for g protein coupled receptors
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002083920A3 Nucleic acid sequences useful in the detection and treatment of various cancers
11/13/2003WO2002079243A3 Gonococcal proteins and nucleic acids
11/13/2003WO2002077609A3 Identification of compounds for the treatment or prevention of proliferative diseases
11/13/2003WO2002072031A3 Substituted tetracycline compounds as synergistic antifungal agents
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002066648A3 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
11/13/2003WO2002057302A8 A virus causing respiratory tract illness in susceptible mammals
11/13/2003WO2002057231A8 Benz(g) indoles and their use as spla2 inhibitors
11/13/2003WO2002056893A8 Novel receptors for $i(helicobacter pylori) and use thereof
11/13/2003WO2002053139A8 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
11/13/2003WO2002050030A8 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
11/13/2003WO2002050029A8 Tetracyclic derivatives as spla2 inhibitors
11/13/2003WO2002040020A9 Novel use of certain insulin sensitizers or ppar-gamma agonists
11/13/2003WO2002036128A9 Neuroactive steroid derivatives and methods of use
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003WO2002032868A8 2-substituted heterocyclic compounds and their use in treating multidrug resistance
11/13/2003WO2002019993A8 Granular preparations for oral administration
11/13/2003WO2002014362A3 A hepatitis c virus non-structural ns3/4a fusion gene
11/13/2003WO2002013826A9 Anti-cancer composition composed of anti-cancer and anti-malarial drugs
11/13/2003WO2001040188A8 Curcumin analogues for treating cancer
11/13/2003US20030213006 Nucleotide sequences comprised of human chorionic gonadotropin (HCG) regulatory sequences for treating and preventing tumors via gene expression inhibition; drug screening
11/13/2003US20030212292 Shortened synthesis of 3,3-diarylpropylamine derivatives
11/13/2003US20030212277 Using 3-sulfonylchloride-4-chloro)pyridine as chemical intermediate
11/13/2003US20030212276 Process for the preparation of 7-substituted-3 quinolinecarbonitriles
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212272 Vasodilation; hypotensive agents; cardiovascular disorders
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212266 Growth arrest homeobox gene
11/13/2003US20030212250 Peptides
11/13/2003US20030212147 Screening drug for activity for overexpression of enzyme
11/13/2003US20030212145 Parkinson's disease; cognition activators; central nervous system disorders
11/13/2003US20030212144 Using monamine oxidase enzyme inhibitor; deprenyl
11/13/2003US20030212142 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
11/13/2003US20030212141 Serotonin antagonists
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212139 Methods, compositions, and kits for enhancing female sexual desire and responsiveness
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212137 Administering a thyroid hormone receptor beta agonist and fibrate to lower triglyceride levels in blood
11/13/2003US20030212136 Creatine ester pronutrient compounds and formulations
11/13/2003US20030212135 Pharmacotherapy for vascular dysfuntion associated with deficient nitric oxide bioactivity
11/13/2003US20030212134 Combination of pinitol and creatine to enhance uptake and retention of creatine
11/13/2003US20030212133 Muscle relaxation; brain disorders; antiepileptic agents
11/13/2003US20030212132 Determination binding of gabapentin to cells
11/13/2003US20030212131 Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
11/13/2003US20030212130 Creatine ester anti-inflammatory compounds and formulations
11/13/2003US20030212129 System and method for revitalizing human skin
11/13/2003US20030212128 Crystalline particles of escitalopram oxalate having a median particle size of >40 mu m; cystallization by gradually cooling the solution of dissolved escitalopram oxalate at a controlled cooling rate; adding crystals of escitalopram oxalate and holding; isolating particles
11/13/2003US20030212127 Method of treating actinic keratosis
11/13/2003US20030212125 Topical applying; skin disorders; antiinflammatory agents
11/13/2003US20030212124 Angiotensin converting enzyme inhibitor; psychological disorders
11/13/2003US20030212123 COX-2 selective carprofen for treating pain and inflammation in dogs
11/13/2003US20030212122 Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene
11/13/2003US20030212119 Novel glucagon receptor antagonists/inverse agonists
11/13/2003US20030212118 Obesity
1 ... 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 5296 ... 7860